Uniunea Europeană - română - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (sub formă de fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - agenți antineoplazici - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. policitemie vera (pv)jakavi este indicat pentru tratamentul pacienților adulți cu policitemie vera, care sunt rezistente la sau intoleranță la hidroxiuree. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Uniunea Europeană - română - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - alte preparate dermatologice - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

novartis pharma gmbh - germania - ruxolitinibum - compr. - 10 mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

novartis pharma gmbh - germania - ruxolitinibum - compr. - 15 mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

novartis pharma gmbh - germania - ruxolitinibum - compr. - 20 mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

novartis pharma gmbh - germania - ruxolitinibum - compr. - 5 mg - inhibitori de protein-kinaza

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenți antineoplazici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Uniunea Europeană - română - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agenți antineoplazici - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd. - cipru - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd. - cipru - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza